Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Ardern-Jones, Michael R. ^{[2
,3
]}

Bieber, Thomas ^{[4
]}

Hong, Chih-Ho ^{[5
,6
,7
]}

Chu, Chia-Yu ^{[8
,9
]}

Liu, Meng ^{[10
]}

Yang, Yang ^{[10
]}

Ladizinski, Barry ^{[10
]}

Teixeira, Henrique D. ^{[10
]}

Calimlim, Brian M. ^{[10
]}

Thyssen, Jacob P. ^{[11
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Hosp Southampton NHS Fdn Trust, Southampton Gen Hosp, Dept Dermatol, Southampton, Hants, England

[3] Univ Southampton, Clin Expt Sci, Fac Med, Southampton, Hants, England

[4] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany

[5] Dr Chih ho Hong Med Inc, Surrey, BC, Canada

[6] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

[7] Prob Med Res, Surrey, BC, Canada

[8] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan

[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[10] AbbVie Inc, N Chicago, IL USA

[11] Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

28032

引用

页码：AB171 / AB171

页数：1

共 50 条

[21] Achieving incrementally greater skin improvement thresholds with upadacitinib in moderate-to-severe atopic dermatitis: a pooled analysis of two phase III studies (Measure Up 1 and Measure Up 2)
Reich, K.
Langley, R. G.
Calimlim, B. M.
Teixeira, H. D.
Zeng, J.
Silverberg, J. I.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E131 - E132
[22] Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies
Blauvelt, Andrew
Silverberg, Jonathan, I
Calimlim, Brian M.
Liu, Yingyi
Platt, Andrew
Thyssen, Jacob P.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[23] Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Prajapati, Vimal H.
Bunick, Christopher G.
Eyerich, Kilian
Gold, Linda Stein
Galimberti, Fabrizio
Calimlim, Brian
Teixeira, Henrique
Hu, Xiaofei
Yang, Yang
Sancho, Cristina
Grada, Ayman
Irvine, Alan D.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[24] Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Silverberg, Jonathan, I
De Bruin-Weller, Marjolein
Bieber, Thomas
Soong, Weily
Kabashima, Kenji
Costanzo, Antonio
Rosmarin, David
Lynde, Charles
Liu, John
Gamelli, Amy
Zeng, Jiewei
Ladizinski, Barry
Chu, Alvina D.
Reich, Kristian
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 977 - +
[25] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
Silverberg, Jonathan I.
Gooderham, Melinda J.
de Bruin-Weller, Marjolein S.
Papp, Kim A.
Aoki, Valeria
Paller, Amy S.
Ofori, Sarah
Tenorio, Allan R.
Liu, Yingyi
Liu, Jianzhong
Chovatiya, Raj
CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
[26] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Reich, Kristian
Teixeira, Henrique D.
de Bruin-Weller, Marjolein
Bieber, Thomas
Soong, Weily
Kabashima, Kenji
Werfel, Thomas
Zeng, Jiewei
Huang, Xiaohong
Hu, Xiaofei
Hendrickson, Barbara A.
Ladizinski, Barry
Chu, Alvina D.
Silverberg, Jonathan I.
LANCET, 2021, 397 (10290): : 2169 - 2181
[27] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
Simpson, Eric L.
de Bruin-Weller, Marjolein S.
Prajapati, Vimal H.
Calimlim, Brian M.
Teixeira, Henrique D.
Zeng, Jiewei
Liu, Meng
Silverberg, Jonathan I.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB60 - AB60
[28] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
Guttman-Yassky, Emma
Teixeira, Henrique D.
Simpson, Eric L.
Papp, Kim A.
Pangan, Aileen L.
Blauvelt, Andrew
Thaci, Diamant
Chu, Chia-Yu
Hong, H. Chih-Ho
Katoh, Norito
Paller, Amy S.
Calimlim, Brian
Gu, Yihua
Hu, Xiaofei
Liu, Meng
Yang, Yang
Liu, John
Tenorio, Allan R.
Chu, Alvina D.
Irvine, Alan D.
LANCET, 2021, 397 (10290): : 2151 - 2168
[29] Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results
Silverberg, Jonathan I.
Eyerich, Kilian
de Bruin-Weller, Marjolein
Calimlim, Brian M.
Platt, Andrew M.
Wu, Tianshuang
Ladizinski, Barry
Thyssen, Jacob P.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB134 - AB134
[30] Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
Magnolo, Nina
Cameron, Michael C.
Shahriari, Mona
Geng, Bob
Calimlim, Brian M.
Teixeira, Henrique
Hu, Xiaofei
Yang, Yang
Liu, Yingyi
Zhang, Shiyu
Sanchez, Cristina Sancho
Altman, Katherine
Langley, Richard G.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)

← 1 2 3 4 5 →